Latest stories on ATOS
Atossa Therapeutics reports Q3 EPS (56c) vs. ($1.01)
The Fly34 · bearishearnings
Atossa Therapeutics reports Q3 results
Business Insider50 · neutralearnings
ATOSSA THERAPEUTICS, INC. (ATOS) files 8-K
SEC 8-K50 · neutralgeneral
Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
PR Newswire50 · neutralearnings
Atossa Therapeutics says common stock to begin trading with stapled CVR
The Fly56 · neutralgeneral
Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today
PR Newswire50 · neutralgeneral
ATOSSA THERAPEUTICS, INC. (ATOS) files 8-K
SEC 8-K50 · neutralgeneral
Atossa Therapeutics enters Stapled Contingent Value Rights Agreement
The Fly58 · neutralm&a
Atos positioned as a Leader in cybersecurity solutions and services in the 2026 ISG Provider Lens™ report for France
GlobeNewswire63 · neutralproduct/pr
Atossa Therapeutics Introduces CVR Plan for Voucher Upside
TipRanks56 · neutralproduct/pr
ATOSSA THERAPEUTICS, INC. (ATOS) files 8-K
SEC 8-K50 · neutralgeneral
ATOSSA THERAPEUTICS, INC. (ATOS) files 8-K
SEC 8-K50 · neutralgeneral
Atossa Therapeutics reports Q2 EPS (95c) vs. (98c) last year
The Fly49 · neutralearnings
Atossa Therapeutics GAAP EPS of -$0.95
Seeking Alpha28 · bearishearnings
ATOSSA THERAPEUTICS, INC. (ATOS) files 8-K
SEC 8-K50 · neutralgeneral
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
PR Newswire50 · neutralearnings
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
PR Newswire24 · bearishgeneral
Atossa Therapeutics prices up to $16.5M direct offering
Seeking Alpha28 · bearishgeneral
ATOSSA THERAPEUTICS, INC. (ATOS) files 8-K
SEC 8-K50 · neutralgeneral